These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 30568661)

  • 1. Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy.
    Bazhin AV; Amedei A; Karakhanova S
    Front Immunol; 2018; 9():2878. PubMed ID: 30568661
    [No Abstract]   [Full Text] [Related]  

  • 2. [Not Available].
    Caux C; Bay JO
    Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors.
    Hui E
    J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 5. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 6. Adverse events associated with immune checkpoint inhibitor treatment for cancer.
    Esfahani K; Meti N; Miller WH; Hudson M
    CMAJ; 2019 Jan; 191(2):E40-E46. PubMed ID: 30642824
    [No Abstract]   [Full Text] [Related]  

  • 7. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The "immune checkpoints", how does it work].
    Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
    Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Masterful Antibodies: Checkpoint Blockade.
    Lonberg N; Korman AJ
    Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Groundbreaking basic research].
    Helland Å
    Tidsskr Nor Laegeforen; 2018 Dec; 138(20):. PubMed ID: 30539600
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials.
    Sen S; Carmagnani Pestana R; Hess K; Viola GM; Subbiah V
    Ann Oncol; 2018 Dec; 29(12):2396-2398. PubMed ID: 30307530
    [No Abstract]   [Full Text] [Related]  

  • 13. Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.
    Asmar N; Ibrahim T; Rey JF
    Dig Dis Sci; 2018 Sep; 63(9):2177-2179. PubMed ID: 29982987
    [No Abstract]   [Full Text] [Related]  

  • 14. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Gastrointestinal Flora in the Treatment of Cancer with Immune Checkpoint Inhibitors.
    Mendoza L
    Klin Onkol; 2018; 31(6):465-467. PubMed ID: 30545227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors.
    Perez-Santos M
    Pharm Pat Anal; 2020 Sep; 9(5):149-154. PubMed ID: 32960139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
    De Silva P; Aiello M; Gu-Trantien C; Migliori E; Willard-Gallo K; Solinas C
    Int J Cancer; 2021 Jul; 149(1):31-41. PubMed ID: 33252786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint inhibitor immunotherapy in kidney cancer.
    Xu W; Atkins MB; McDermott DF
    Nat Rev Urol; 2020 Mar; 17(3):137-150. PubMed ID: 32020040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
    Sweis RF; Luke JJ
    Pharmacol Res; 2017 Jun; 120():1-9. PubMed ID: 28323141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissecting the mechanisms of immune checkpoint therapy.
    Sharma P; Allison JP
    Nat Rev Immunol; 2020 Feb; 20(2):75-76. PubMed ID: 31925406
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.